Deucravacitinib: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

6 February 2024

  • curprev 22:3122:31, 6 February 2024‎ Kosar Doraghi talk contribs‎ 26,216 bytes +418‎ No edit summary
  • curprev 21:1821:18, 6 February 2024‎ Kosar Doraghi talk contribs‎ 25,798 bytes +25,798‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Deucravacitinib (SOTYKTU) |aOrAn=a |drugClass=tyrosine kinase 2 (TYK2) inhibitor |indicationType=treatment |indication=treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy |hasBlackBoxWarning=Yes |adverseReactions=hypersensitivity reaction, upper respiratory infections, blood creatine phosphokinase increased,..."
Retrieved from "https://www.wikidoc.org/index.php/Deucravacitinib"